# EDGAR Filing Document

**Accession Number:** 0001697532
**File Stem:** 0001193125-26-049942
**Filing Date:** 2026-2
**Character Count:** 3584
**Document Hash:** 77d232c6d8aa389144cdeade03f21d8f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-049942.hdr.sgml**: 20260213

**ACCESSION NUMBER**: 0001193125-26-049942

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260213

**DATE AS OF CHANGE**: 20260213

**EFFECTIVENESS DATE**: 20260213

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Applied Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001697532
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38898
- **FILM NUMBER:** 26629041

**BUSINESS ADDRESS:**
- **STREET 1:** 545 FIFTH AVENUE, SUITE 1400
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** 212-220-9226

**MAIL ADDRESS:**
- **STREET 1:** 545 FIFTH AVENUE, SUITE 1400
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Applied Therapeutics Inc.
- **DATE OF NAME CHANGE:** 20170208

**As filed with the Securities and Exchange Commission on February 13, 2026** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM 15** 

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION** 

**UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)** 

**OF THE SECURITIES EXCHANGE ACT OF 1934.** 

**Commission File Number: 001-38898** 

## Applied Therapeutics, Inc.
**(Exact name of registrant as specified in its charter)** 

**545 Fifth Avenue, Suite 1400** 

**New York, NY 10017** 

**(Address, including zip code of registrant's principal executive offices)** 

**Common stock, $0.0001 par value per share** 

**(Title of each class of securities covered by this Form)** 

**None** 

**(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)** 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
|  Rule 12g-4(a)(1) | ☒ |
|  Rule 12g-4(a)(2) | ☐ |
|  Rule 12h-3(b)(1)(i) | ☒ |
|  Rule 12h-3(b)(1)(ii) | ☐ |
|  Rule 15d-6 | ☐ |
|  Rule 15d-22(b) | ☐ |

---

Approximate number of holders of record as of the certification or notice date: One (1).\*

\* <u>Explanatory Note</u>: Pursuant to the Agreement and Plan of Merger, dated as of December 11, 2025, by and among Cycle Group Holdings Limited, a private limited company incorporated in England and Wales ("<u>Parent</u>"), AT2B, Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("<u>Purchaser</u>") and Applied Therapeutics, Inc., a Delaware Corporation (the "<u>Company</u>"), Purchaser merged with and into the Company with the Company surviving the merger as an indirect wholly owned subsidiary of Parent. The merger became effective on February 3, 2026, upon the filing of the certificate of merger with the Secretary of State of the State of Delaware. 

------

Pursuant to the requirements of the Securities Exchange Act of 1934, Applied Therapeutics, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: February 13, 2026

---

| | |
|:---|:---|
| **APPLIED THERAPEUTICS, INC** | **APPLIED THERAPEUTICS, INC** |
| By: | /s/ James Harrison |
| Name: | James Harrison |
| Title: | President |

---